what does it mean for novo going forward?they push ahead with this drug or look at alternatives? >> they are, and the normal sense on friday it was encouraged by the results. it still intends to launch the drug in the market in 2026. i think we are still waiting for a lot of details around this trial, and novo said it will release more information next year, and i think there are big questions to be answered. for example, novo during this trial allowed patients if they want to do to remain on the lower dose instead of the stepping up to a higher dose, and a lot of patients decided to do that, and that may have impacted they had led results, and the big question now is why did patients decide to stay on the lower dose? is it because of side effects, and which case that is not a good story for novo, but it could be a more positive one of may be patients were simply just happy with the slower weight loss, so there are a lot of details that will come out that will help us better assess the future of the drug and novo's future pip

the drugs maker novo nordisk, the name behind ozempic and wegovy, is now europe's most valuable company. so how could food, exercise, cosmetics and weight—loss brands all be shaken up by these new drugs? i'll find out from barclays' head of european pharmaceutical research — that's emily field — and the research director to some of the world's biggest blue chip companies, toby clark of mintel consulting. plus, later in the show, our big boss is polina veksler, the co—founder and chief executive of universal standard. it makes clothes for those who are size zero to size a0. is the jab juggernaut simply hype or a real game—changer with trillion—dollar consequences? wherever you'rejoining us from, welcome to the programme. now, in 1983, a married couple, jenny and sid craig, opened their first weight—loss centre in melbourne, australia. it grew to be a global company with 700 slimming clubs and a food brand so big that nestle bought it for $600 million. well, last year, after changing hands a few more times, jenny craig filed for bankruptcy. all its employees were let go and the brand name

novo nordisk following the most on record. failed event to leapfrog eli lilly in the market because of novo's experimental obesity shot missing the target. that brings us to the stock of the hour is eli lilly. for more on this, we are joined by jared holz, managing director at mizuho securities. the result of this experimental drug by novo nordisk missed the target, but not by a lot. is is a proportional response by eli lilly to the novo nordisk news? jared: there is so much complexity to it. when you look at the data on a relative basis versus what the company message and what investors were thinking, it definitely came up short. in absolute terms, the data in terms of efficacy very solid. but when you look at what eli lilly currently has, it seems like lilly will still be the market leader as the combination is not good enough to really supersede it. scarlet: is there a lot of hammering for a new obesity drug that novo nordisk is working on? the current ones seem to be effective. jared: i agree with you. that has been a big

novo nordisk has not been fazed by the competition, though.is industry, when we talk about obesity, then all the market potential is so big that there's more than enough space for two or even more competitors. so that's the starting point. and then, in the pharmaceutical industry, this is really competition on innovation. so what exactly do these drugs do? the main ingredient is called semaglutide or tirzepatide. they both act on a receptor in the body called glp—1. it basically makes you feel fuller for longer and helps regulate insulin and blood sugar in the body, hence its original use for diabetes. in 2023, semaglutides were the biggest—selling class of drugs in the united states. around $14 billion worth were given. it's estimated that in the us alone, 137 million people could be eligible for the drug. there are forecasts that the global market for these drugs by 2029 will be worth $126 billion. and this is just the legitimate market. demand is such that an underground market has emerged, with increasingly dangerous consequences. michelle

francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbuster diabetes and obesity drugs ozempic and wegovy. both contain the key ingredient semaglutide, revolutionizing the weight loss market and generating billions in sales. celebrities have helped their popularity soar. sharon osbourne, chelsea handler, and elon musk have all publicly talked about taking ozempic or wegovy, and they've had further backing from oprah winfrey. it's a global phenomenon, reaching millions on social media apps, including tiktok. but it's not without controversy, including possible side effects, high prices, and the company's lobbying efforts receiving criticism around the world. and in some cases, patients might also need to take the drugs indefinitely to avoid regaining the weight. chief executive lars fruergaard jorgensen says obesity is a disease and thinks the company will learn from its growing number of patients. lars: when i ask the scientists, they say the priority and mechanism will tell you that it's chronic treatment. my personal view is that we will als

the stock is up 30 some percent year-to-date and novo is down. and so to keep the momentum, they have to have a good 4 q. >> when you look at the classes of drugs, we're talking about weight loss. whether it is 20% or 25%, that is the right area. is next metric going to be muscle mass? and will other candidates really start entering into the fray >> well, that is a very good point. we've talked about muscle mass and quality of weight loss right now there is no way to get that approved by the fda so we have to have some regulatory updates so what is most important is maintaining the weight, good tolerability, this derailed the novo program and more extended dosing frequency dosing once a month, every other month and that is why they were interested in the other drug. >>> does the stumble prove that the smaller players have a shot in this game either by commercializing a product or being bought because it was thought a week ago that these two big players have such a deep pipeline that the smaller players may not have a place in the race. >> this is

volkswagen and novo nordisk.n you've got the news out of japanese which is seismic for the industry we'll talk about it next year, maybe. sector gains and losers. one sector moving up really. properly moving up healthcare losers healthcare with a gainer on novo nordisk. down is travel and leisure they clawed back a little bit. all i can say to our audience stateside and europe, good luck. if you are getting on a plane, good luck. the airports are chaotic right. >>> the united states congress averted a government shutdown bypassing spending legislation on saturday. it was saturday. it wasn't friday night we had a shutdown for 38 minutes. nothing happened trust me this after government funding expired at midnight. chris pollone joins us from washington my goodness me, we talk about the world, chris, d.c. how exciting is that >> reporter: never a dull moment that is the truth here they thought they had a deal in place last wednesday everything looked great. republicans and democrats thought they were going home for

>>> olympic maker novo nordisk , novo nordisk diving while their competitor is up 3.5%. we will talk to analysts who say we are nearing an inflection point for the tired dob one space. we are back after this . >>th i> iss the exchange on cnbc. big news for mahomes! i'm switching to iphone 16 pro at t-mobile! it's built for apple intelligence. that's like peanut butter on jelly... on gold. get four iphone 16 pro on us, plus four lines for $25 bucks. what a deal. ya'll giving it away too fast t-mobile, slow down. to go further, you need to be ready for what's down the road. as energy demand continues to rise, we're harnessing breakthrough innovations to increase production in the u.s. gulf of mexico. our latest deepwater development, anchor, produces previously inaccessible oil and natural gas, allowing us to deliver the energy we all need today so everyone can follow their own road. that's energy in progress. z's bakery is looking to add a pizza oven, arissa's hair salon wants to expand their space, and steve's t-shirt shop wants to bring on more help. with the comcast bu

>> the story a lot last week we had novo data disappointed most.to zepbound. that's kind of not part of the picture now. my focus turns to 4 q where expectations are still pretty high. i think for the full-year consensus or guidance is really important. next year consensus is $28 billion for all of lilly's zepbound and mounjaro, about 26, that's going to set the tone. we're focused on that, and i think that will be -- >> the adverse surprise for novo, is there any read through at all, either pro or con for lilly or the area? i wonder how fast the challengers might ho>> lilly's the best products. toppling that will be challenging. novo had lofty expectations and failed to meet them. >> talk about biogen. falls into the kind of cheap, maybe for a reason, bucket we were very excited about he can mav which was approved in 2023. it wasn't a cure but it was a way to help patients. it seems like they're kind of stuck in a rut. my view it goes back under invested in the pipeline for a long time. they prioritize share buybacks over buying assets and we're s

, seeing that at 72 weeks s versus 68 weeksh novo, that the side effects were lower? >> right, it's a good question we showed that patients on zepbound lost about 50 pounds, compared to the competitor, wegovy, patients lost 33 pounds. and we noted that the tolerability of the drug, the adverse effects, were similar to what we've seen in previous trials for each of the two drugs. and previous trials, we've seen that zepbound is -- is generally well tolerated the most common side effects are, as you point out, the nausea and vomiting and diarrhea, which still happens in a fraction of patients, most of those patients actually stay on the drug and get the benefit. the study wasn't designed to compare. the safety of the two drugs. but of course, we're presenting that data at a scientific meeting, and we're excited about what we saw, not just in the efficacy, but also the tolerability profile of zepbound in this trial as it's demonstrated in previous trials. >> this is a great implication in terms of the ability to market, saying, you know, your drug zepbound is more effect

he was based half a mile from novo nordisk.tely for those businesses, its meaning less growth and also for the danish economy means that all growth is centered around this one company and now at the expense of others. that create some sort of concentration risk that could become a problem for denmark down the road. tom: i wonder if they look at nokia. >> the number one solution that government and low -- local municipalities are looking at is opening up borders to attract more leaders from a from -- from abroad. we seen initiatives easing restrictions. the opening of international schools in international colleges. ex-pat tax benefit schemes. this approach is controversial in denmark because across the political spectrum and also the danish population there are many people who don't want more immigrants, so there are limitations to how much the danish government can open its borders if denmark already has one of the strictest immigration policies in europe for that reason. in the meantime danish companies are really just left t

novo nordisk down by more than 22%.xperimental obesity shot losing less weight than predicted in a study. that stock is getting hammered. eli lilly up in the premarket by close to 11%. more on the story in moment. trump threatens the eu with tariffs. ♪ jonathan: coming into friday, a three-day losing streak on the s&p 500, the longest going back to october. negative by 0.8%. down 1.3 on the nasdaq. down 1.4% on the russell. small caps, getting hammered. two year, 10-year, 30 year. 10 year, down by two basis points but up on the week by double digits. 4.54. it is not the shifting perception of the federal reserve and the drop of the e-zine. it is also the data, retail sales, jobless claims, consumption numbers. gdp, they have been pretty good. lisa: which is now putting a renewed focus on inflation, which is the reason why the the pce, the key data point that the fed looks at might be pretty interesting. if it surprises to the upside, how much does this reemphasize the hawkish tinge we heard from the fed. jonathan: let's

novo did a study that showed clinically that people lose clinically meaningful weight. on their medicine you lose 13 to 15% of your body weight. on air as you lose 20 two journey 6%. -- on hours you lose 20 to 26%. david: there was a study that came out a couple days ago that said one on one comparing the two, your drug, anti-obesity drug loses weight more rapidly for people than the other product. dave: more rapidly and more. 47% more. after a year and half, people on our drug lost 17 more pounds. david: why do people need to lose so much weight in this country? our country has 75% of the people overweight and 42% are obese. when did that happen when we went to no-fat food? when did we become so obese? dave: if you look at the epidemiology charts, it seems to have started in the 1960's, growth in overweight and obesity in the country. and really accelerated in the 1980's and 1990's. what are the reasons? how we live certainly is one of them. energy expenditure has to be part of the story. what we need has to -- probably more important reason, not just the quantity, whi

you know, novo doesn't have one of these next generation pills.me to come. >> got to leave it there. thank you so much. >> thank you. >> emily field. >>> coming up on the other side of this a new era ahead for crypto currency. we'll talk about how president-elect trump's pick for sec chair will impact digital assets and the crypto industry. >> and the netflix -- you know, netflix delivering the netflix for christmas taking on the nba. what this could mean for the future of streaming and major sporting events. all that and more as "squawk box" rolls on a day after christmas and hanukkah. (♪♪) car, this isn't the way home. that's right james, it isn't. car, where are we going? we're here. (♪♪) surprise!!! the future isn't scary. not investing in it is. car, were you in on this? nothing gets by you james. nasdaq-100 innovators. one etf. before investing, carefully read and consider fund investment objectives, risks, charges, expenses and more in prospectus at invesco.com ♪ ♪ investment objectives, ris with so much greates entertainment out there... w

that will be exciting for novo nordisk.pace will benefit from the innovation and new use cases for glp-1s. >> we await for the announcements. that was the cio at tema. >>> coming up on the show, german chancellor olof scholz is preparing for a no-confidence vote as they look ahead to the likely election in february. we'll have details after this break. ah, these bills are crazy. she has no idea she's sitting on a goldmine. well she doesn't know that if she owns a life insurance policy of $100,000 or more she can sell all or part of it to coventry for cash. even a term policy. even a term policy? even a term policy! find out if you're sitting on a goldmine. call coventry direct today at the number on your screen, or visit coventrydirect.com. >>> woman >>> welcome to "street signs." i'm amaro amaro.silvia amaro. here are your headlines. >>> moody's slashes the france credit rating with the new prime minister who seeks compromise in the parliament. >> translator: if i may, in my turn, i will erve the wreck as you will reconcil

i love novo at this price.ley: you know, jacob, many, you know, market observe ors will ten you it's great -- will tell you it's great we've had the leadership we've had from big tech and a.i., but it's not a broad-based advance, and that is always a sign of a more healthier market, would you agree? >> i would. and over the last few weeks, you look at many areas outside of tech and a lot of them are beaten down, but over the course of this entire bull market we've gotten decent participation. it's hard to the compete with nvidia, you know, going up a million times, you know, over less than five years, right? but when you look outside of big tech, there are opportunities. when i look, i mean, there are opportunities down 10% in the last few weeks, down more than 10% in the last few weeks. going into january 2025 the with an economy that's still growing, a fed that the i know we're wondering about how many rate cuts we're going to get, but it's a fed that has made clear if it can cut rates, it will. and, by the w

great american story >> let's get to novo as well >> absolutely, david >> we talk so often about novo nordisk, one of the two beneficiaries of the weight loss drugs that have revolutionized the ability for people to lose weight, deal with obesity. the stock is getting crushed you don't need to read it there, you can just look at it. in the stock chart that we're about to show you. why? well, their trial, their long awaited closely monitored trials at 68 weeks, called redefine one, graphic you see, safety and investigating a shot, a once a week shot, that was anticipated, the best way i can put it, guys, to take weight loss down as much as 25% over that time period it took it down 22.7%. you may say, well, gee, that seems pretty effective and pretty statistically significant. apparently not enough, jim, for the investors in novo. or i should say that this was a success. >> no, i thought it was going to do 25% it was obviously something that got too hyped. lilly is better, that's why lilly's stock is up. at one point, their stock was up 80 that seemed to be aggressive lilly has the bett

novo nordisk is one of the biggest european, not going out of business and this is just a gimme, the novo nordisk but the other two are a little bit more american, cat is a big industrial name but on sale and considering this new economy going into new president, new administration, hopefully a new economy global economy, cat should benefit and verizon is a very boring name. nothing is sexy about verizon at all but it's a great dividend payer, pays about 7% for owning it and it trades in this 38 to $45 trading range and now it's kissing at 39 at the moment and it's finding plenty of support but i think on weakness, verizon is another name i own and we own it but on weakness i'd be adding to my verizon just because that name offers to your portfolio and stability. >> let's look at the macrostory on the s&p 500 because right now the most bullish call we've seen is above 7,100. do you think that we've got enough momentum in 2025? i know there's a new administration and question mark on tariffs and congress and spending and all that kind of goes into the soup of whether or not we'll have

novo's wegovy, 17%.s do 25 and it didn't happen, you've got a problem for shareholders was the market is extremely competitive. and this was not a pill. stuart: my favorite subject. down 20% almost. or all right, move on. trump, i believe he made some kind of move with his shares of djt. he's not selling them? if. lauren: no, he's not. he's moving them into a trust. he transfer thed his entire stake, which is worth over $4 billion or just over half of the company. djt down today, it's more than doubled this year because the president-elect will be president in a few days. stuart: address bitcoin, because that's having a rough day. >> lauren: it's at 95,000 now. it hit 108 just a couple days ago. cathie wood, her ark fin-tech fund offloaded almost $4 million of coinbase, the largest crypto exchange. stuart: and that's gone down too. the tesla rally. man, that's lost some steam, hasn't it? if look at it, another 3%? lauren: between bitcoin and tesla, this is the trump trade. and if djt at that too. so tesl

eli lilly hospice weight loss drug winning over novo nordisk.ion of obesity drugs. let's get to 35 thousand feet and talk about the adoption of these. i'm sure in your world is busy. talk about the adoption and whether things have slowed or where you are still seeing the steep grove we saw over the previous year. evan: let's go back to three q results where we saw a bifurcation between eli lilly and novo. they were trying to draw demand in line with what you described. novo still had supply issues with assets like week ovi -- weg ovy. let's talk about the date it, largely expected but eli lilly has data that can go out to physicians to say ours is better. what is important is that novo has a data read out by the end of the year and could be better by zetbond. we found a trial posted on the website for clinical trials showing that novo has a co-formulation. a lot of moving parts, very exciting. fourth quarter is important because companies got beaten up in 3q. jonathan: what is better about it, delivery, performance, more effective? evan: weight

the company which makes them, novo nordisk, is already the biggest in europe by quite some way, but whatnsumer areas like food and fashion? my colleague, ben thompson, has been speaking to the director of research for the consulting arm of the company that calls itself the world's leading market intelligence agency. it's still really early days at the moment. some of the stuff we're seeing coming through, first of all, is in the supplement sector. so obviously if people are taking in fewer calories, they want to make sure they're getting all the nutrients that they need. so in the us especially, we've seen a couple of brands that have launched supplements specifically for glp one users. we've also seen it in some of the us retail stores, where we've got one of the health food firms creating special glp one drug areas in the store to help guide people through their requirements. it's already hitting multiple sectors. we're seeing it in cosmetics, where you're seeing more claims coming through about skin plumping to try and counteract that "ozempic face" challenge. and nestle, for example,

shares of novo nordisk shares are down more than 20%.tting hit right now on ointing weight loss data shares of eli lilly up 8%. novo nordisk shares falling on disappointing data when it comes to the weight loss area. that is it for "worldwide exchange." "squawk box" starts right now. >>> good morning it is 18 hours until midnight and a shutdown is now looming. a last-minute deal to fund the government was defeated in the house after 38 republicans ignored president-elect trump and voted against it we're going to take you live to washington >>> plus, starbucks baristas are going on strike today. details straight ahead. >>> and the faa banning drones in the state of new jersey what the department of homeland security said about that move. it is friday, december 20th, 2024 and "squawk box" begins right now. >>> good morning, everybody. welcome to "squawk box" here on cnbc we are live from the nasdaq market site in times square. i'm becky quick along with joe andrew ross sorkin joe is off today let's check out what's happening with the marke

eli lilly rising on novo's trial results by about 2.6%.look at avocado seller mission. it's speaking 19% after its fourth quarter results beat on the top and bottom line thanks to higher avocado prices. the key ingredient to guacamole saw prices spike 36% year-over-year due to weather disruptions in peru. mission produce reaping the benefits as adjusted profits rose 160% year-over-year. and this has been a story we've been following particularly over the past several months. united states steel shares, u.s. steel, melting down about 5% after the flat-rolled steel producer forecast it's going to report a surprise fourth quarter loss due to lower prices and volumes. the company also reduced its outlook saying "steel prices remain depressed." russia using all of the weapons in its arsenal to attack ukraine overnight, but the ballistic missiles and drones may not be the scary of weapons . the cyberattack russia just unleashed on ukraine's government databases could be worse. the ceo of online security app okta protects the u.s. government syst

you can check it out novo nordisk shares are down 22%. in the meantime, shares of eli lilly and other weight loss drug companies are jump ing on the news eli lilly shares up 10% this morning and viking up by a similar amount close to 10% as well >>> we have more coming up on "squawk box" this morning. nike forecasting lower margins for the holiday quarter as it liquidates ventory as part of the turn around strategy we will ask have an exclusive with john williams about the fed's ability to cut back rates next year. we'll talk about it in the 8:00 hour all that and more s "squawk box" continues after this. at pgim, finding opportunity in fixed income today, helps secure tomorrow. our time-tested fixed income suite, backed by over 145 years of risk experience, helps investors meet their goals. pgim investments. shaping tomorrow today. ehh... hmm. oh, that's very, uh... - right? - mmm... this store doesn't have agentforce, so an ai agent didn't tip off the stylist as to what i might actually wear. - yes. - oh. that's a commitment. [glass kno

score because the judges when they're confirm need to be told, are you going to actually exercise de novo review under exemption one or not? but that's not going to happen. the second issue i wanted to raise with you is the difficulty that congress has in oversight function, because the executive branch is so secret. they throw up state secrets, executive privilege, sometimes it's nothing. and i'm wondering at the inherent power the u.s. supreme court has affirmed. saying congress can even put people in prison without any hearing. if they refuse to comply with the subpoena for testimony or documents. this goes back to the daugherty case almost 100 years old. why isn't that used as -- to get information in a timely fashion? as you point out, you put in a foia request, it's politically stale even by the time, eastbound if you win, when it gets back. what's your assessment of using the inherent contempt policy? thomas: with your first observation on the main case and classification, keep in mind that the exemption one refers to classified under executive order. the president writes the execu

we've got a lot of, you know, candidates out there, oral candidates, including ones by novo as well ashy could this be best in class? which is what you said in the press release. >> yeah, thank you, melissa. so, i know you know a lot about this space. we don't yet have an oral approved therapy, and we also have seen a lot of data from orals to say that we can see effective weight loss. we don't yet have that ideal drug where you see really good tolerability along with that weight loss, something that's very scaleable from a manufacturing standpoint. and available. i've also heard you talk about, you know, different patient segments in this market, different therapies could be appropriate for them. so, we don't think there's going to be one winner in the oral glp-1 race. >> do you see -- do you see your oral drug being more of a maintenance drug as opposed to the drug that you're on to lose that initial, you know, big portion of the body weight that needs to be lost? >> yeah, you know, i think people are talking about that in general for orals, and it's going to depend on the patient an

you have politicians as well as now the companies, pfizer, novo nordisk in a testimony against them.he companies are fighting back. john: that is putting it strongly. they have always been at its with pharma. not surprising to hear pharma companies criticizing pbm's. they are on the opposite sides of negotiating tables. what is not often understood broadly, pbm's see themselves as the counter to unchecked drug prices. in a free market, companies could set the price as high as they want. pbm see themselves as bundling purchasing power and trying to negotiate discounts off of the prices that the manufacturer set. sonali: john tozzi, thank you. looking forward to your reporting. i look at real estate markets through the lens of giant planned communities, as bill ackman looks to take howard hughes private. an interview with the company ceo is next. ♪ to go further, you need to be ready for what's down the road. as energy demand continues to rise, we're harnessing breakthrough innovations to increase production in the u.s. gulf of mexico. our latest deepwater development, anchor, produces

lily's zepbound and novo's wegovy. who won, taylor? >> sepp -- zepbound.ponsored by eli lilly, with but this was the first sort of head to head match that we to got, and we got the results. people on zepbound lost about 20 percent of their weight or on average 50 pounds in about 72 weeks versus just 14% of the body weight using novo nordisk's drug. so eli lilly, at least in the first head to head a, the winner. so stuart south to stuart okay, got that. apple, they just revealed whose a.i. chip they're using. this is important. whose chips are they using? >> amazon. can you believe that? so sort of competitors become partners in many cases. it's the aws which is amazon's cloud unit, their custom a.i. chip. they said they're evaluating if apple can also use it for if things like apple intelligence, but so far they've been a great partner in terms of using a work s for siri, music and other thing for the apple products. stuart: this is what ray wang was just talking about, the right? >> they did. so we're in the middle of this amazons investor conference whic

perdida de peso z-bound ha demostrado que no es un perdida de demostrado ser mas efectivo que wengobi de novore, el ensayo clinico tomo 72 semanas. >> los pacientes que recibieron cepa perdieron en promedio mas del 20 por ciento en comparacion con el 13% de aquellos que recibieron el medicamento wegovit. >> segun eli lilly esto representa un 47% mas de perdida de peso con z-bound frente a weigobi precisamente. >> y ademas en este estudio participaron 751 adultos de estados unidos y puerto rico y todos con sobrepeso y tambien obesidad. >> aunque zed down mostro ser mas efectivo en terminos de perdida de peso, wegovi tiene tiene beneficios adicionales para la salud del corazon. >> invernal tormenta invernal atraviesa los grandes lados de la tambien el noreste del pais. >> las nevadas son intensas, hay fuertes vientos y lluvia helada y esto va a continuar. >> el mal tiempo ya dejo imagenes como las que ven en su pantalla en ohio, por ejemplo, el peso de la nieve provoco el colapso de un techo en una e escuela y un lavadero de autos en en pensilvania, un bloque de hielo destruruyo el parabrisas u

back in the spotlight with senator bernie sanders writing, unless medicare demands that drugmakers novoprix emiums for all seniors would skyrocket. earlier this year, the ceo of novo nordisk told lawmakers they're working to bring costs down, but also blamed the complex u.s. healthcare system and one final note, we reached out to robert f. kennedy jr. and dr. oz's teams about this proposed rule and so far we have not gotten a response. >> maggie vespa, thank you very much. appreciate that. >>> coming up next, a sunday sit-down with a music icon, billy joel, reflecting back on five decades of writing and playing some of the most famous songs in the history of music. >>> and then, a life well lived. the barrier-breaking pioneer in education and business. >>> as we head to brk, our photo of the week, a stunning first look inside the restored notre dame cathedral. look at that, restored to full glory after that devastating fire five years ago. the french president emmanuel macron and his wife taking a tour inside, saying it is in their words even more beautiful than before. notre dame offic

eli lilly beat novo nordisk in a head to head study comparing the two weight loss drug treatments.a clinical trial revealed that eli lilly's zip bound provided 47% more weight loss on average than wegovy. results showed patients got weekly injections of eli lilly. they lost weight an average of 50 pounds after 72 weeks. that's compared to an average of 33 pounds for those who got the novo nordisk injection during that same time frame. calls for change in san jose what a new report is revealing about conditions at the san jose animal center, and the improvements that could be on the way. plus, we continue to follow that developing story in new york, where the ceo of united health was shot to death outside of a hotel. what witnesses say they saw and ho police kill the ceo of insurance company unitedhealthcare. police are describing the killing as a quote, brazen, targeted attack and not a random act of violence. brian thompson had just walked out of his hotel in manhattan this morning, when the gunman walked up and shot him and continued to fire as thompson fell to the ground. it was

. >> in response to the study, novo nordisk, the maker of wegovy, saying in part wegovy is the only obesitye proven to reduce the risk of major cardiovascular events such as death, heart attack or stroke in adults with known heart disease and with either obesity or overweight. >> i've taken vyvanse, topiramate, phentermine fen-phen when it was on the market. i've taken wegovy, but anything that's been out there, i can guarantee you that i've been prescribed that for years. >> barbara goudreau has been searching for a solution to help her reach her weight loss goals. >> girl, i've been trying to lose weight so long that i felt like i should invite the weight management people to my thanksgiving, she says. >> in 2022, she was on the highest dose of wegovy you could take, but didn't see results, she says after her insurance. no longer covered the drug, she tried a few other medications until her doctor put her on manjaro and in june switched to zep bound. both of those drugs have the active ingredient tirzepatide. >> i switched to manjaro because wegovy wasn't working, so my doctor kept saying

take a look at the shares of novo nordisk.ug. shares fell about 20% on friday, shedding more than $90 billion in market cap squawk box is coming right back. thank you! guys, can you keep it down. i'm working. you people are (guitar noises). hand over the air guitar. i've got another one. prime, it's me. i mean, you. wake up, come on man! you gotta tell employers to take another look at all the benefits they're offering. everybody wants to build the best team and offering aflac can help attract and retain that top talent. you know we like that top talent. and listen, i mean you gotta listen. aflac gives employees cash to help with unexpected medical bills. it's prime time to add aflac. request a call today at aflac.com/prime (♪♪) (♪♪) (♪♪) everyone has goals and dreams. and everyone deserves a way to get there. wherever you're going, getting there starts here. state street invest in your future with dia, the only etf that tracks the dow. (♪♪) >>> it is kind of cool, isn't it? everything goes around on these tracks. did you see

es el genérico de medicamento de novo nordisk.ica, elecciones internacionales. y es que las elecciones presidenciales de los estados unidos, las de méxico y las de venezuela, se posicionaron en el primer lugar en la lista de los temas más buscados entre los latinos. y es que dieron mucho de qué hablar. marta mijares habló con expertos de google. nos tiene todo sobre los temas de más interés de la comunidad. a punto de cerrar el año 2024, la empresa google entrega un listado de los eventos y temas de actualidad que más cautivaron al público con su lista de lo más buscado. las noticias de política y eventos meteorológicos fueron los más populares. temas de noticias yo creo que fueron de gran impacto durante este año. año de elecciones. definitivamente creo que las elecciones acapararon la atención de muchos este año y está en la primera posición de la lista de tendencias en noticias, las olimpiadas, el huracán milton. lo interesante es de que este año no vimos tanto búsquedas alrededor de personas. mucha gente se preguntó qué es un

eli lilly's weight loss drug zepbound helped people lose more weight than novo nordisk's wegovy.govy. >>> the price of bitcoin has hit $100,000. it has surged 45% since election day. >>> there is a famous pair of ruby slippers worn by judy garland in the wizard of oz up for auction. and bidding has already surpassed $1 million. the final live auction happens this saturday in texas. i'm sure it's going to be huge now with all the rave around wicked. >>> the mega millions jackpot has grown to $579 million. that is the tenth largest in its history after no one won the latest drawing, the cash option is worth $276.6 million. the next drawing is tomorrow night. what a great holiday season it would be if you won. season it would be if you won. ♪♪ mmmmmmm. repeat the sounding joy. [laughters] kinder joy. [laughters] open a world of surprise. my life is full of questions... mom, is yellow a light or a dark? how do i clean an aioli stain? thankfully, tide's the answer to almost all of them. why do we even buy napkins? —use tide. —can cold water clean white socks? it can with tide. do i ne

i'll just buy another factor was the highly nationalist brazilian regime of the startle novo, the advisor to you about a guess, just because you put a stop to those effort last night and ensure that state one schools were set up in these areas. and then i noticed it said to nobody in my family state sky anymore except me. my parents generation didn't learn the language promptly and didn't policy don't often. well, it took decades for the next generation to begin to take an interest in that job and family history. again, the research, the cemetery and hold on to the grace of german name. some of my grandmother's foster parents that had songs that buried here so is my grandma eat a meal for my grandmother passed away. 1997, a been thoughtful. she died. she trying to make contact with our sisters in germany, but unfortunately she didn't use excel is look at my city and half a sore each other. again, the last 21 of her niece has came the visit her grades and i was a very emotional moment. so much the 2 years out of my father had been to germany at matthew's german cousins for the 1st time ran

oral experimental contra la obesidad por un valor de hasta 2 mil millones de dólares, mientras que de novolas tasas de interés para este tipo de préstamos a 30 años, según mortgage bankers association, la tasa de interés del préstamo hipotecario más popular en estados unidos subió al 6.75% la semana pasada, de 6.67%. mientras tanto, el volumen en las solicitudes para refinanciamiento bajaron un 3% la semana pasada. yo soy silvana henao y este es tu informe cnbc para telemundo. durante esta época del año, muchos celebramos las posadas navideñas. son tradiciones que se caracterizan por los rezos, cánticos y las representaciones bíblicas del momento en que la virgen maría y san josé buscaban refugio en belén. de acuerdo al catolicismo, además de la unión familiar y de amigos. otros elementos son los dulces y piñatas y alimentos como tamales y ponche. pero este año para muchos ha menor cantidad, ya que la inflación ha afectado los bolsillos de los consumidores. y es que desde octubre se registró un aumento del 2% en los alimentos, lo que llevó a algunas familias a recortar ese presupuesto para

also fears he doesn't like the obesity drugs that weighed on the makers of these like eli lilly and novo nordisk but some say the sectors is over sold with recent upgrades by the recent drugmaker biontech. >> we've got stocks like pfizer, merck, and j & j actually down on the year and there could be opportunities there. i'd point to pfizer which is near 52 week low around 25 with about a 7% dividend yield the stock which looks pretty safe. i'd also highlight covid vaccine maker moderna which is under 40 right now down about 60% with almost half its market cap in cash. >> 7% dividend sounds pretty nice. one of the few bright spots has been humana since the election, because of the idea that the medicare rules might change, that would help in its favor. >> that's right there's some talks a republican administration will be more favorable to medicare advantage which is of course the privately-run alternative to traditional medicare and that would benefit humana which is a pure medicare advantage play and they might benefit from increased government payment rates next year. >> which is good

. >> and i'm karina novo.mcdonald's in pennsylvania. and as we've discovered, he has bay area ties. reporter anthony johnson from our sister station in new york has the latest. >> the suspect has been in custody since about 930 this morning. he traveled some 230 miles from new york city to altoona, pennsylvania. he was in a local mcdonald's when a worker recognized him and called worker police. they came in and took the suspect into custody. 26 year old luigi mangione sits in a jail cell in altoona, pennsylvania, arrested on gun charges, and cops believe he is the man seen in video shooting and killing unitedhealthcare ceo brian thompson. >> and officers recovered a firearm on his person, as well as a suppressor, both consistent with the weapon used in the murder. they also recovered clothing, including a mask consistent with those

it's a generic version of novo nordisk's drug victoza, which has been in shortage since last year.comes after another company called teva pharmaceuticals launched their version of victoza earlier this year. hikma pharmaceuticals says it expects the drug to be available nationwide before the end of the year. nordstrom is going private. today, the company announced it agreed to a buyout deal valued at over $6 billion. the deal is between nordstrom's founding family and mexican department store el puerto de liverpool. it will give the nordstrom family a majority ownership stake in the company. the deal comes as nordstrom and other department stores are facing pressure from discount chains and competition. retailer company for mblicly traded or a legend. before tonight's warriors game, the team honored the life of rickey henderson, baseball's man of steel. the message, posted on social media warriors said his impact will be remembered and celebrated for generations to come. henderson died on friday. he was 65 years old. all right. now to the game. warriors taking on the indiana pacers

novo nordisk lower into the scoop. on the day down 2.5%, ozempic linked to a rare vision loss risk. patients should be aware, which seems like a significant risk. the weight loss had been popular. the big stock story, broadcom soaring up 20%, best day since they hit public in '09. the quarter was ok. the ai forecast is boosting, the ai component business is growing 65% by '27, a $90 billion market. ai is alive and well. scarlet: thank you. details on what broadcom told us and what we can infer. ian king covering the company in the u.s. and across asia. the latest member of the $1 trillion club. it predicted demand in ai chips. give us a sense of scale. we heard big numbers. does this put broadcom in the same league as nvidia? ian: we have two trillion dollar companies. the growth forecasted is sensational. the hint was $90 billion from the type of chip it helps companies make. nvidia's data centers will be more than $100 billion this year. broadcom is a strong second player but has a way to go. scarlet: what about the non-ai businesses, parts for cars, smartphones, internet access a

we have some breaking lines crossing from the maker of ozemp ic, novo nordisk.g to invest around 1.2 billion u.s. dollars in a new factory in denmark. it's already been ramping up investment to build out capacity to meet the demand for its weight loss and obesity drugs and it expects that and a new ticket on that front when it comes to investing domestically in denmark again. it is a new facility. they will also be thinking about a facility to focusing -- focus on rare disease and hemophilia drugs. that's a stock we will be watching at the open. let's check in on the markets now with european futures looking for direction, currently pointing lower by .1%. the ftse 100 and similar territory. we have losses of european and u.s. stocks last week and globally stocks year to date have gained about 20%. nasdaq 100 futures looking to add 10 points. it's a massive week for the central banks of the world and you will be getting the federal reserve basis points, followed by the bank of japan and the bank of england, which is expected to standpat. yields jumped around 20 b

novo nordisk a bit after the drug trial missed expectations, the stock is up 4%. >> it is this good rebounddecline that they had on friday given the big pullback. basically it was a late stage trial and they wanted to see a 25% weight loss after 68 weeks patient only had 22.7% weight decline clearly not workable and not meeting the skyhigh expectations. the stock this morning rebounding they wanted to further testing but it clearly beat the placebo effect just not meeting the 25% level that they had set out for investors. ashley: you covered a lot of ground with style. thank you very much. let's take a look at the big board why don't we. the dow off more than 100 points, down 114. a bit of the headwind as a rising treasury yield that tends to her equities and that's at play. the dow only offer quarter of 8% right now let's take a look at the dow winners there are some out there, let's take a look, there they are nvidia we just talked about nvidia up 2% in the early going, nike, merck, verizon, unitedhealth moving higher, nike up 1% right now let's take a look at the s&p 500 winners, brad, a

. >>-- novo nordisk. >> it's creating adverse effects with these drugs. inodata. >> talked about palantir and going for them and that's another ai play and under the radar ai play and in a data providing services to all the major ai players and they are the service provider and pick and shovel play growing at tremendous rate accelerating from 35% to 65% to now over 135% and stocks hitting new high. stuart: yes, it is. thank you, lieu. indata >> who is he going with him today? reporter: he's on capitol hill and really digging his heels in and media turning him in for brett kavanagh that and not going to stand for that and not bowing out and going on offense and penned an article in the wall street journal that says in part "it's a textbook manufactured media take down. talk to those that served with me in guantanamo bay, iraq, or national guard. they support me and i'm honored by that . i've never backed down from a fight and won't from this one. i look forward to an honest confirmation hearing from the distinguished senators and not a show trial in the pr